US 12,410,116 B2
Compounds and use thereof in methods of treatment
Mathias Francois, St. Lucia (AU); Johannes Zuegg, Wynnum (AU); Jeroen Overman, The Hague (NL); Sreeman Kumar Mamidyala, Hyderabad (IN); Angela Aguslyarti Salim, Durack (AU); Frank Roger Fontaine, Kenmore (AU); Matthew Allister Cooper, Cambridge (GB); Robert John Capon, Pullenvale (AU); and Avril Alexis Barbara Robertson, Kenmore (AU)
Assigned to The University Of Queensland, St. Lucia (AU)
Filed by The University of Queensland, Queensland (AU)
Filed on Jun. 27, 2023, as Appl. No. 18/342,312.
Application 18/342,312 is a continuation of application No. 17/741,065, filed on May 10, 2022.
Application 17/741,065 is a continuation of application No. 16/472,882, granted, now 11,434,190, issued on Sep. 22, 2022, previously published as PCT/AU2017/051439, filed on Dec. 21, 2017.
Claims priority of application No. 2016905362 (AU), filed on Dec. 23, 2016.
Prior Publication US 2024/0002326 A1, Jan. 4, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07C 63/66 (2006.01); A61P 35/00 (2006.01); C07C 39/15 (2006.01); C07C 43/215 (2006.01); C07C 63/331 (2006.01); C07C 233/65 (2006.01)
CPC C07C 63/66 (2013.01) [A61P 35/00 (2018.01); C07C 39/15 (2013.01); C07C 43/215 (2013.01); C07C 63/331 (2013.01); C07C 233/65 (2013.01)] 17 Claims
 
1. A method of treating a SOX7-, SOX17-, or SOX18-dependent cancer, comprising:
administering to a subject whose cancer has been tested for SOX7, SOX17, or SOX18 dependency an effective amount of a compound of Formula I:

OG Complex Work Unit Chemistry
wherein:
R1 is selected from the group consisting of OH and OR6, wherein R6 is C1-4 alkyl;
R2 is selected from the group consisting of H, COOR7, and C(O)NR8R9, wherein R7, R8, and R9 are independently selected from the group consisting of H and C1-4 alkyl;
R3 is L-A, wherein L is a linker selected from the group consisting of C2-8 alkyl, C2-8 alkenyl, and C2-8 alkoxyalkyl, and A is an optionally substituted naphthyl;
R4 is selected from the group consisting of H, OR10, halo, and C1-4 alkyl, wherein R10 is selected from the group consisting of H and C1-4 alkyl; and
R5 is selected from the group consisting of H, OR11, halo, and C1-4 alkyl, wherein R11 is selected from the group consisting of H and C1-4 alkyl;
or a pharmaceutically effective salt, solvate or prodrug thereof.